MacroGenics Yönetim

Yönetim kriter kontrolleri 3/4

MacroGenics CEO'su Scott Koenig, Sep2001 tarihinde atandı, in görev süresi 23.17 yıldır. in toplam yıllık tazminatı $ 3.71M olup, şirket hissesi ve opsiyonları dahil olmak üzere 19% maaş ve 81% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.07% ine doğrudan sahiptir ve bu hisseler € 4.01M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 7.8 yıl ve 7.4 yıldır.

Anahtar bilgiler

Scott Koenig

İcra Kurulu Başkanı

US$3.7m

Toplam tazminat

CEO maaş yüzdesi	19.0%
CEO görev süresi	23.2yrs
CEO sahipliği	2.1%
Yönetim ortalama görev süresi	7.8yrs
Yönetim Kurulu ortalama görev süresi	7.4yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Scott Koenig'un ücretlendirmesi MacroGenics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$98m
Jun 30 2024	n/a	n/a	-US$136m
Mar 31 2024	n/a	n/a	-US$23m
Dec 31 2023	US$4m	US$705k	-US$9m
Sep 30 2023	n/a	n/a	US$50m
Jun 30 2023	n/a	n/a	US$7m
Mar 31 2023	n/a	n/a	-US$91m
Dec 31 2022	US$5m	US$673k	-US$120m
Sep 30 2022	n/a	n/a	-US$191m
Jun 30 2022	n/a	n/a	-US$219m
Mar 31 2022	n/a	n/a	-US$217m
Dec 31 2021	US$5m	US$651k	-US$202m
Sep 30 2021	n/a	n/a	-US$146m
Jun 30 2021	n/a	n/a	-US$129m
Mar 31 2021	n/a	n/a	-US$136m
Dec 31 2020	US$3m	US$656k	-US$130m
Sep 30 2020	n/a	n/a	-US$158m
Jun 30 2020	n/a	n/a	-US$167m
Mar 31 2020	n/a	n/a	-US$152m
Dec 31 2019	US$5m	US$590k	-US$152m
Sep 30 2019	n/a	n/a	-US$166m
Jun 30 2019	n/a	n/a	-US$155m
Mar 31 2019	n/a	n/a	-US$167m
Dec 31 2018	US$5m	US$599k	-US$171m
Sep 30 2018	n/a	n/a	-US$21m
Jun 30 2018	n/a	n/a	-US$34m
Mar 31 2018	n/a	n/a	-US$32m
Dec 31 2017	US$3m	US$554k	-US$20m

Tazminat ve Piyasa: Scott 'nin toplam tazminatı ($USD 3.71M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 786.80K ).

Tazminat ve Kazançlar: Scott 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Scott Koenig (72 yo)

23.2yrs

Görev süresi

US$3,705,825

Tazminat

Dr. Scott Koenig, M.D., Ph D., has been the President and Chief Executive Officer of Macrogenics, Inc. since September 2001. Dr. Koenig is Co-Founder of Macrogenics.He served as Senior Vice President of R...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Scott Koenig	President	23.2yrs	US$3.71m	2.07% € 4.0m
James Karrels	Senior VP	16.5yrs	US$1.58m	0.27% € 529.3k
Stephen Eck	Senior VP of Clinical Development & Chief Medical Officer	4.3yrs	US$1.75m	0.016% € 30.2k
Eric Risser	Chief Operating Officer	2.8yrs	US$1.92m	0.062% € 120.1k
Thomas Spitznagel	Senior Vice President of Technical Operations	2yrs	US$1.88m	0.013% € 25.7k
Ezio Bonvini	Senior VP of Research & Chief Scientific Officer	8.2yrs	US$2.29m	0.16% € 311.5k
Jeffrey Peters	Senior VP	7.4yrs	Veri yok	Veri yok
Lynn Cilinski	VP, Controller & Treasurer	21.1yrs	Veri yok	0.0099% € 19.2k

7.8yrs

Ortalama Görev Süresi

61.5yo

Ortalama Yaş

Deneyimli Yönetim: M55 'un yönetim ekibi deneyimli ve deneyimlidir ( 7.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Scott Koenig	President	23.2yrs	US$3.71m	2.07% € 4.0m
David Stump	Independent Director	11.2yrs	US$160.75k	0.0072% € 13.9k
Federica O'Brien	Independent Director	3.8yrs	US$152.00k	0.0072% € 13.9k
Edward Hurwitz	Independent Director	20.1yrs	US$147.63k	0.060% € 116.0k
Margaret Liu	Independent Director	1.8yrs	US$318.32k	0.0072% € 13.9k
William Heiden	Independent Chairman of the Board	2.5yrs	US$180.13k	0.0072% € 13.9k
Meenu Chhabra Karson	Independent Director	1.8yrs	US$335.41k	0.0072% € 13.9k
Scott Jackson	Independent Director	7.8yrs	US$167.63k	0.0072% € 13.9k
Jay Siegel	Independent Director	7yrs	US$167.21k	0.0072% € 13.9k
Karen Jean Ferrante	Independent Director	7.8yrs	US$135.75k	0.0072% € 13.9k

7.4yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: M55 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.4 yıldır).

MacroGenics Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Scott Koenig Intends to Step Down as Chief Executive Officer of MacroGenics, Inc., Early Next Year

Insider recently bought €67k worth of stock

MacroGenics, Inc. Appoints Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

Macrogenics, Inc. Approves the Appointment of Margaret Liu, M.D. to Serve as Director

Senior VP recently bought €95k worth of stock

MacroGenics, Inc. Announces Management Changes

Recent updates

Third quarter 2024 earnings released: EPS: US$0.90 (vs US$0.28 in 3Q 2023)

Scott Koenig Intends to Step Down as Chief Executive Officer of MacroGenics, Inc., Early Next Year

MacroGenics, Inc. Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024

Second quarter 2024 earnings released: US$0.89 loss per share (vs US$0.93 profit in 2Q 2023)

Macrogenics Provides Vobramitamab Duocarmazine Update

MacroGenics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Block & Leviton Files Lawsuit Against MacroGenics, Inc

New major risk - Financial position

First quarter 2024 earnings released: US$0.84 loss per share (vs US$0.61 loss in 1Q 2023)

MacroGenics, Inc. Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

Full year 2023 earnings released: US$0.15 loss per share (vs US$1.95 loss in FY 2022)

Investor sentiment improves as stock rises 15%

MacroGenics, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Investor sentiment improves as stock rises 20%

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 21%

Third quarter 2023 earnings released: EPS: US$0.28 (vs US$0.40 loss in 3Q 2022)

MacroGenics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Insider recently bought €67k worth of stock

Investor sentiment deteriorates as stock falls 16%

New major risk - Share price stability

Second quarter 2023 earnings released: EPS: US$0.93 (vs US$0.67 loss in 2Q 2022)

MacroGenics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: US$0.61 loss per share (vs US$1.08 loss in 1Q 2022)

MacroGenics, Inc. to Report Q1, 2023 Results on May 09, 2023

Full year 2022 earnings released: US$1.95 loss per share (vs US$3.37 loss in FY 2021)

Macrogenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients

MacroGenics, Inc. Appoints Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

Macrogenics, Inc. Approves the Appointment of Margaret Liu, M.D. to Serve as Director

MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab

Third quarter 2022 earnings released: US$0.40 loss per share (vs US$0.86 loss in 3Q 2021)

MacroGenics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Second quarter 2022 earnings released: US$0.67 loss per share (vs US$0.67 loss in 2Q 2021)

MacroGenics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

MacroGenics, Inc. Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer

Senior VP recently bought €95k worth of stock

MacroGenics, Inc. Announces Management Changes

First quarter 2022 earnings released: US$1.08 loss per share (vs US$0.90 loss in 1Q 2021)

Insufficient new directors

MacroGenics, Inc. to Report Q1, 2022 Results on May 03, 2022

MacroGenics, Inc., Annual General Meeting, May 19, 2022

MacroGenics, Inc. Announces Promotion of Eric Risser to Chief Operating Officer

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

MacroGenics, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Third quarter 2021 earnings released: US$0.86 loss per share (vs US$0.66 loss in 3Q 2020)

MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA in Patients with HER2-Positive Metastatic Breast Cancer

Second quarter 2021 earnings released: US$0.67 loss per share (vs US$0.94 loss in 2Q 2020)

Insufficient new directors

MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting

First quarter 2021 earnings released: US$0.90 loss per share (vs US$0.91 loss in 1Q 2020)

Full year 2020 earnings released: US$2.47 loss per share (vs US$3.16 loss in FY 2019)

Revenue beats expectations

MacroGenics, Inc. Provides Update Proprietary Programs

New 90-day low: €16.00

MacroGenics, Inc. to Report Q4, 2020 Results on Feb 25, 2021

MacroGenics, Inc. Names Federica O’Brien to its Board of Directors

New 90-day low: €16.30

Macrogenics, Inc. Announces the Publication of Results from the Sophia Trial of Margenza

Macrogenics, Inc. Announces Research Collaboration and Global License Agreement to Develop Preclinical Bispecific Molecule with Janssen Biotech, Inc

MacroGenics, Inc. Announces FDA Approval of MARGENZA for Patients with Pretreated Metastatic HER2-Positive Breast Cancer

MacroGenics Presents Flotetuzumab Data in Patients with Refractory Acute Myeloid Leukemia At the 2020 ASH Annual Meeting

MacroGenics, Inc. and EVERSANA Announces Agreement to Support the Potential Launch and Commercialization of Margetuximab

Revenue beats expectations

Third quarter 2020 earnings released: US$0.66 loss per share

MacroGenics Announces Flotetuzumab and Tebotelimab Presentations at the ASH Annual Meeting 2020

MacroGenics, Inc. to Report Q3, 2020 Results on Nov 04, 2020

MacroGenics, Inc. Enters into A Commercial Supply Agreement with Incyte Corporation

MacroGenics Announces Flotetuzumab Publication in Blood Advances

New 90-day low: €20.80